Terumo Corporation Acquires OrganOx for $1.5bn

Symeres Acquires Organix Inc.

April 26, 2022

Biotechnology

Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.

Quanterix Corporation Acquires Akoya Biosciences

July 8, 2025

Medical Devices

Quanterix Corporation has completed its acquisition of Akoya Biosciences, combining Quanterix's ultra‑sensitive blood biomarker detection platform with Akoya's spatial biology imaging and reagents. Under the amended merger agreement, Quanterix issued approximately 7.8 million shares and paid about $20 million in cash to Akoya equity holders; the combined business is expected to expand the company's served addressable market and accelerate the path to profitability.

WuXi AppTec Completes Acquisition of OXGENE

March 2, 2021

Biotechnology

WuXi AppTec, via its cell and gene therapy unit WuXi Advanced Therapies (WuXi ATU), completed the acquisition of Oxford-based OXGENE on March 2, 2021. The purchase brings OXGENE's gene-therapy discovery and viral-vector manufacturing technologies into WuXi ATU, expanding its capabilities and establishing its first European facility to better serve global cell and gene therapy customers.

Terumo Corporation Acquires Health Outcomes Sciences, Inc.

February 24, 2021

Cloud & SaaS

Terumo Corporation has entered a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc., including the ePRISM predictive analytics and clinical decision support platform. The acquisition will expand Terumo's digital healthcare capabilities by integrating ePRISM into Terumo Business Edge to deliver patient-specific predictive insights at the point of care and improve outcomes while lowering costs.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

Organon Acquires Alydia Health

June 16, 2021

Medical Devices

Organon completed its acquisition of Alydia Health, a commercial-stage medical device company focused on preventing postpartum hemorrhage, for total consideration of $240 million (including up to $25 million in contingent milestones). The deal expands Organon’s portfolio into medical devices and leverages its global commercial footprint to broaden access to Alydia’s Jada System for maternal hemorrhage worldwide.